Soligenix announces positive anthrax vaccine stability results

Soligenix, a development stage biopharmaceutical company, announced positive results on Wednesday from long-term stability studies into its SGX204 anthrax vaccine.

The vaccine is a proprietary dominant negative inhibitor anthrax recombinant protective antigen subunit protein vaccine developed to protect against anthrax as a pre-exposure prophylactic vaccine or a post-exposure vaccine.

Stability in the SGX204 vaccine was demonstrated when subjected to temperatures that reached as high as 158 degrees Fahrenheit for one month. The vaccine was also found to be stable after refrigerated storage for more than seven years.

When the vaccine was combined with a potent adjuvant formulation, it was also found to result in high titer neutralizing antibodies conferring protection against anthrax disease in animals.

"We are very excited about these extraordinary stability results," Robert N. Brey, the chief scientific officer of Soligenix, said. "We believe that the combination of long-term stability over several years with stability at such elevated temperatures has the potential to confer a distinct advantage over other anthrax vaccine technologies currently in development. Further, SGX204 is highly immunogenic and thereby offers the potential for complete immunization with just one or two doses. As with any biodefense product, our goal is to have SGX204 stockpiled by the US government."

Initial development work on SGX204 is covered pursuant to a $9.4 million contract with the National Institute of Allergy and Infectious Disease. The contract covers engineered variants of PA developed in the Harvard Medical School laboratory of John Collier. Soligenix said that the Collier anthrax vaccine can be developed to have an efficacy profile superior to that of other anthrax vaccines.